Daron Evans Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 10,000 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the purchase, the chief financial officer now directly owns 237,900 shares of the company’s stock, valued at $687,531. The trade was a 4.39 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Rezolute Price Performance

RZLT opened at $2.93 on Friday. The business has a 50 day moving average price of $4.26 and a two-hundred day moving average price of $4.75. The company has a market capitalization of $177.37 million, a price-to-earnings ratio of -2.40 and a beta of 0.95. Rezolute, Inc. has a 1-year low of $2.22 and a 1-year high of $6.19.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. Equities analysts expect that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RZLT has been the topic of a number of analyst reports. Craig Hallum raised shares of Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. JMP Securities boosted their price objective on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 13th. Guggenheim reissued a “buy” rating on shares of Rezolute in a report on Monday, February 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Rezolute in a research note on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $24.38.

Institutional Investors Weigh In On Rezolute

Institutional investors and hedge funds have recently bought and sold shares of the business. Alpine Global Management LLC bought a new stake in shares of Rezolute in the 4th quarter worth approximately $54,000. Woodline Partners LP grew its position in Rezolute by 2,817.1% in the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company’s stock worth $5,338,000 after buying an additional 1,052,002 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Rezolute by 48.5% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock valued at $97,000 after buying an additional 6,470 shares in the last quarter. Point72 Europe London LLP acquired a new stake in shares of Rezolute during the 4th quarter valued at $720,000. Finally, Man Group plc bought a new stake in shares of Rezolute during the 4th quarter worth $425,000. 82.97% of the stock is owned by institutional investors and hedge funds.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.